X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (31318) 31318
Newsletter (165) 165
Book Chapter (36) 36
Dissertation (16) 16
Magazine Article (8) 8
Publication (7) 7
Book Review (6) 6
Web Resource (6) 6
Book / eBook (5) 5
Conference Proceeding (5) 5
Newspaper Article (3) 3
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21360) 21360
cisplatin (16614) 16614
cisplatin - pharmacology (11967) 11967
oncology (11702) 11702
female (10723) 10723
animals (10242) 10242
antineoplastic agents - pharmacology (8857) 8857
male (8435) 8435
chemotherapy (8075) 8075
pharmacology & pharmacy (7714) 7714
cancer (7502) 7502
cell line, tumor (7027) 7027
apoptosis (6062) 6062
mice (5305) 5305
middle aged (5096) 5096
cisplatin - administration & dosage (4670) 4670
apoptosis - drug effects (4440) 4440
aged (4280) 4280
adult (4146) 4146
antineoplastic combined chemotherapy protocols - therapeutic use (3798) 3798
expression (3308) 3308
biochemistry & molecular biology (3084) 3084
cell survival - drug effects (2922) 2922
dose-response relationship, drug (2912) 2912
rats (2744) 2744
tumor cells, cultured (2674) 2674
drug resistance, neoplasm (2662) 2662
lung neoplasms - drug therapy (2529) 2529
cell proliferation - drug effects (2360) 2360
cisplatin - therapeutic use (2354) 2354
antineoplastic agents - therapeutic use (2240) 2240
research (2194) 2194
cisplatin - adverse effects (2175) 2175
drug resistance (2165) 2165
carcinoma (2157) 2157
treatment outcome (2110) 2110
cytotoxicity (2072) 2072
tumors (2051) 2051
ovarian neoplasms - drug therapy (2050) 2050
resistance (2047) 2047
cell biology (2043) 2043
analysis (2039) 2039
cisplatin - toxicity (1979) 1979
antineoplastic agents (1965) 1965
toxicity (1885) 1885
drug synergism (1865) 1865
antineoplastic combined chemotherapy protocols - adverse effects (1856) 1856
care and treatment (1801) 1801
proteins (1767) 1767
in-vitro (1740) 1740
therapy (1729) 1729
antimitotic agents (1718) 1718
ovarian cancer (1697) 1697
inhibition (1674) 1674
carboplatin (1646) 1646
lung neoplasms - pathology (1627) 1627
activation (1616) 1616
mice, nude (1611) 1611
cells (1588) 1588
platinum (1571) 1571
paclitaxel (1564) 1564
dna damage (1556) 1556
carcinoma, non-small-cell lung - drug therapy (1546) 1546
antineoplastic agents - administration & dosage (1527) 1527
cancer therapies (1522) 1522
dna (1522) 1522
antineoplastic agents - chemistry (1510) 1510
time factors (1474) 1474
lung cancer (1459) 1459
ovarian neoplasms - pathology (1456) 1456
survival (1433) 1433
antineoplastic agents - adverse effects (1398) 1398
gene expression (1397) 1397
health aspects (1383) 1383
neoplasms - drug therapy (1376) 1376
toxicology (1373) 1373
medicine, research & experimental (1364) 1364
oxidative stress (1355) 1355
drug screening assays, antitumor (1346) 1346
cell line (1324) 1324
medicine & public health (1318) 1318
chemistry, medicinal (1303) 1303
drugs (1276) 1276
pharmacology/toxicology (1267) 1267
xenograft model antitumor assays (1263) 1263
antineoplastic combined chemotherapy protocols - pharmacology (1261) 1261
combined modality therapy (1229) 1229
metastasis (1226) 1226
organoplatinum compounds - pharmacology (1215) 1215
nephrotoxicity (1203) 1203
drug resistance, neoplasm - genetics (1193) 1193
prognosis (1192) 1192
antineoplastic agents - toxicity (1179) 1179
doxorubicin (1174) 1174
growth (1171) 1171
doxorubicin - pharmacology (1153) 1153
combination (1152) 1152
cell cycle (1144) 1144
drug administration schedule (1140) 1140
mice, inbred balb c (1125) 1125
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (30930) 30930
Japanese (649) 649
Chinese (462) 462
Russian (90) 90
French (74) 74
German (58) 58
Portuguese (30) 30
Spanish (29) 29
Dutch (22) 22
Polish (15) 15
Italian (11) 11
Ukrainian (5) 5
Korean (4) 4
Czech (3) 3
Hebrew (2) 2
Slovak (2) 2
Amharic (1) 1
Croatian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2008, Volume 134, Issue 7, pp. 2004 - 2013
Background & Aims: Chemotherapy with an anticancer agent generally causes gastrointestinal tract disorders such as vomiting and anorexia, but the mechanism... 
Gastroenterology and Hepatology | SEROTONIN RECEPTOR | GHRELIN LEVELS | SYMPTOMS | MICE | EMESIS | GASTROENTEROLOGY & HEPATOLOGY | STOMACH | Receptor, Serotonin, 5-HT2B - metabolism | Receptor, Serotonin, 5-HT2C - metabolism | Body Weight - drug effects | Drugs, Chinese Herbal - pharmacology | Male | Stomach - metabolism | Drugs, Chinese Herbal - metabolism | Anorexia - physiopathology | Quinolines - pharmacology | Serotonin Receptor Agonists - pharmacology | Dose-Response Relationship, Drug | Serotonin 5-HT2 Receptor Antagonists | Chalcones - pharmacology | Dopamine Antagonists - metabolism | Receptors, Ghrelin - metabolism | Indoles - pharmacology | Stomach - innervation | Stomach - drug effects | Drugs, Chinese Herbal - therapeutic use | Flavones - pharmacology | Acylation | Disease Models, Animal | Antineoplastic Agents | Rats | Thiophenes - pharmacology | Anorexia - metabolism | Dopamine Antagonists - therapeutic use | Receptors, Ghrelin - drug effects | Piperazines - pharmacology | Rats, Sprague-Dawley | Vagotomy | Cisplatin | Ghrelin - metabolism | Eating - drug effects | Gastrointestinal Agents - pharmacology | Ghrelin - blood | Animals | Dopamine Antagonists - pharmacology | Aminopyridines - pharmacology | Serotonin - metabolism | Gastrointestinal Agents - therapeutic use | Anorexia - prevention & control | Hesperidin - pharmacology | Protein Binding | Anorexia - chemically induced | Oligopeptides - pharmacology | Gastrointestinal Agents - metabolism | Medicine, Botanic | Medicine, Herbal
Journal Article
The Journal of biological chemistry, ISSN 0021-9258, 12/2001, Volume 276, Issue 50, pp. 47107 - 47115
Journal Article
Apoptosis, ISSN 1360-8185, 4/2013, Volume 18, Issue 4, pp. 393 - 408
Journal Article
Cancer research (Chicago, Ill.), ISSN 0008-5472, 07/2017, Volume 77, Issue 14, pp. 3870 - 3884
Effective targeted therapies for small-cell lung cancer (SCLC), the most aggressive form of lung cancer, remain urgently needed. Here we report evidence of... 
GENE | SIGNATURES | ONCOLOGY | BIOLOGY | RESISTANCE | PARP | MODEL | MUTATIONS | IDENTIFICATION | Piperazines - administration & dosage | Lung Neoplasms - drug therapy | Humans | Pyrazines - administration & dosage | Small Cell Lung Carcinoma - enzymology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cisplatin - administration & dosage | Gene Knockdown Techniques | Biomarkers, Tumor - metabolism | Female | Pyrazoles - pharmacology | Lung Neoplasms - genetics | Phthalazines - administration & dosage | Checkpoint Kinase 1 - antagonists & inhibitors | Small Cell Lung Carcinoma - genetics | Cisplatin - pharmacology | Piperazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Drug Synergism | Checkpoint Kinase 1 - metabolism | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Pyrazoles - administration & dosage | Small Cell Lung Carcinoma - pathology | Animals | Mice, Nude | Cell Line, Tumor | Mice | Pyrazines - pharmacology | Checkpoint Kinase 1 - genetics | Medical research | Cell culture | Effectiveness | Small cell lung carcinoma | RNA-mediated interference | CHK1 protein | Lung cancer | Clinical trials | Poly(ADP-ribose) polymerase | Pharmacology | Myc protein | Kinases | Cisplatin | Anticancer properties | Amplification | Inhibitors | Platinum | Biomarkers | Antitumor activity | Inhibition | Cancer
Journal Article
Clinical cancer research, ISSN 1557-3265, 2006, Volume 12, Issue 8, pp. 2640 - 2646
Purpose: Tumor necrosis factor-related apoptosis–inducing ligand (TRAIL/Apo2L) exhibits potent antitumor activity on systemic administration in nonhuman... 
apoptosis | TRAIL | primary human hepatocytes | chemotherapy | in-vivo | tumoricidal activity | monoclonal-antibody | hepatocellular-carcinoma cells | human hepatocytes | receptor | death | nf-kappa-b | family | apoptosis-inducing ligand | HEPATOCELLULAR-CARCINOMA CELLS | APOPTOSIS-INDUCING LIGAND | ONCOLOGY | HUMAN HEPATOCYTES | IN-VIVO | RECEPTOR | TUMORICIDAL ACTIVITY | MONOCLONAL-ANTIBODY | DEATH | NF-KAPPA-B | FAMILY | Immunohistochemistry | Apoptosis Regulatory Proteins - pharmacology | Apoptosis - drug effects | Gene Expression - genetics | Humans | Tumor Necrosis Factor-alpha - genetics | GPI-Linked Proteins | Apoptosis - genetics | Deoxycytidine - pharmacology | Hepatocytes - metabolism | Receptors, TNF-Related Apoptosis-Inducing Ligand | Organoplatinum Compounds - pharmacology | Receptors, Tumor Necrosis Factor, Member 10c | Dose-Response Relationship, Drug | Tumor Necrosis Factor Decoy Receptors | Hepatocytes - cytology | TNF-Related Apoptosis-Inducing Ligand | Time Factors | Apoptosis Regulatory Proteins - genetics | Antineoplastic Agents - pharmacology | Hepatocytes - drug effects | Camptothecin - analogs & derivatives | Receptors, Tumor Necrosis Factor - genetics | Receptors, Tumor Necrosis Factor - metabolism | Cell Survival - drug effects | Membrane Glycoproteins - pharmacology | Cells, Cultured | Etoposide - pharmacology | Cisplatin - pharmacology | Recombinant Proteins - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Membrane Glycoproteins - genetics | Tumor Necrosis Factor-alpha - pharmacology | Cell Line, Tumor | Fluorouracil - pharmacology | Camptothecin - pharmacology | Deoxycytidine - analogs & derivatives
Journal Article
Cancer medicine (Malden, MA), ISSN 2045-7634, 2017, Volume 6, Issue 11, pp. 2646 - 2659
Malignant pleural mesothelioma (MPM), an asbestos‐related occupational disease, is an aggressive and incurable tumor of the thoracic cavity. Despite recent... 
Afuresertib | cancer therapy | Mesothelioma | Akt inhibitor | MULTIPLE-MYELOMA | CARCINOMA-CELLS | APOPTOSIS | ACTIVATION | TRASTUZUMAB RESISTANCE | BREAST-CANCER | ONCOLOGY | PATHWAY | PROSTATE-CANCER | PHASE-I | PROGRESSION | Caspase 7 - metabolism | Apoptosis - drug effects | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Caspase 3 - metabolism | Phosphorylcholine - analogs & derivatives | Heterocyclic Compounds, 4 or More Rings - pharmacology | Pleural Neoplasms - drug therapy | Quinoxalines - pharmacology | Oxadiazoles - pharmacology | Phosphorylcholine - pharmacology | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Inhibitory Concentration 50 | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Pyrazoles - pharmacology | Thiadiazoles - pharmacology | Forkhead Box Protein O1 - metabolism | Thiophenes - pharmacology | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Glycogen Synthase Kinase 3 beta - metabolism | Mesothelioma - drug therapy | Pyrroles - pharmacology | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | G1 Phase Cell Cycle Checkpoints - drug effects | Benzylamines - pharmacology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Proteins | Analysis | Cell proliferation | Phosphorylation | Asbestos | Cell survival | Caspase | Cytotoxicity | Occupational diseases | AKT protein | Thorax | Myc protein | Cisplatin | Western blotting | 1-Phosphatidylinositol 3-kinase | Cyclin-dependent kinase inhibitor p21 | Cell number | Cell cycle | Forkhead protein | Apoptosis | G1 phase
Journal Article
Cancer research (Chicago, Ill.), ISSN 1538-7445, 2013, Volume 73, Issue 12, pp. 3683 - 3691
Replication stress and DNA damage activate the ATR-Chk1 checkpoint signaling pathway that licenses repair and cell survival processes. In this study, we... 
CHECKPOINT KINASE 1 | IN-VITRO | ONCOLOGY | XANTHINE DERIVATIVES | DNA-DAMAGE RESPONSE | PROTEIN-KINASE | TUMOR-CELLS | MYELOGENOUS LEUKEMIA-CELLS | RADIOSENSITIZING AGENT | MAMMALIAN-CELLS | CHK1 INHIBITOR | Protein Kinases - metabolism | Protein Kinases - genetics | Humans | Ovarian Neoplasms - pathology | Cell Survival - genetics | Deoxycytidine - pharmacology | Immunoblotting | Sulfones - pharmacology | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | RNA Interference | BRCA1 Protein - metabolism | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Cycle Proteins - genetics | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | Phosphorylation - drug effects | cdc25 Phosphatases - metabolism | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - pharmacology | Cell Survival - drug effects | Topotecan - pharmacology | Cell Cycle Proteins - metabolism | Protein-Serine-Threonine Kinases - genetics | Signal Transduction - genetics | cdc25 Phosphatases - genetics | Ataxia Telangiectasia Mutated Proteins | Cisplatin - pharmacology | Pyrimidines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors | BRCA1 Protein - genetics | Poly(ADP-ribose) Polymerases - metabolism | BRCA2 Protein - metabolism | Signal Transduction - drug effects | Cell Line, Tumor | Benzimidazoles - pharmacology | Checkpoint Kinase 1 | Pyrazines - pharmacology | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | homologous recombination | ovarian cancer | Poly(ADP-ribose) polymerase | veliparib | gemcitabine | BRCA1 | cisplatin | BRCA2 | topotecan
Journal Article
Clinical cancer research, ISSN 1557-3265, 2005, Volume 11, Issue 20, pp. 7508 - 7515
Purpose: BRCA2, FANCC , and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to... 
BRCA1, BRCA2 | Xenograft models | DNA damage and repair mechanisms | Pharmacogenetics/pharmacogenomics | Gastrointestinal cancers: other | GENE-MUTATIONS | LUNG-CANCER | FUNCTIONAL-ACTIVITY | ONCOLOGY | ABL TYROSINE KINASE | MITOMYCIN-C | PANCREATIC-CANCER | RANDOMIZED-TRIAL | PHASE-II | COMPLEMENTATION GROUP | CARCINOMA | Paclitaxel - pharmacology | Apoptosis - drug effects | Cross-Linking Reagents - pharmacology | Humans | Deoxycytidine - pharmacology | Chlorambucil - pharmacology | Fanconi Anemia Complementation Group C Protein - genetics | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Caspases - metabolism | Fanconi Anemia Complementation Group G Protein - genetics | Time Factors | Cross-Linking Reagents - therapeutic use | Fanconi Anemia Complementation Group G Protein - deficiency | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Melphalan - pharmacology | Cell Survival - drug effects | Fanconi Anemia Complementation Group Proteins - deficiency | Mitomycin - therapeutic use | Pancreatic Neoplasms - pathology | Fanconi Anemia Complementation Group Proteins - genetics | Etoposide - pharmacology | Pancreatic Neoplasms - genetics | Cisplatin - pharmacology | Xenograft Model Antitumor Assays - methods | Mitomycin - pharmacology | Animals | Mice, Nude | Cell Line, Tumor | Fanconi Anemia Complementation Group C Protein - deficiency | BRCA2 Protein - deficiency | Fluorouracil - pharmacology | Mice | Vinblastine - pharmacology | Mutation | Cell Cycle - drug effects | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology
Journal Article
The Journal of biological chemistry, ISSN 1083-351X, 2000, Volume 275, Issue 50, pp. 39435 - 39443
Journal Article
British journal of cancer, ISSN 0007-0920, 08/2014, Volume 111, Issue 4, pp. 716 - 725
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2012, Volume 30, Issue 3, pp. 1248 - 1256
This study sought to measure the degree of synergy induced by specific small molecule inhibitors of DNA-PK [NU7026 and IC486241 (ICC)], a major component of... 
Anthracyclines | DNA-PK | Medicine & Public Health | Homologous recombination | Non-homologous end joining | Oncology | DNA-damage | Breast cancer | Pharmacology/Toxicology | DNA-repair | Drug synergism | PHOSPHORYLATION | DEPENDENT PROTEIN-KINASE | DOUBLE-STRAND BREAKS | OXALIPLATIN | DAMAGE | REPAIR | ONCOLOGY | COLORECTAL-CANCER | COMBINATION CHEMOTHERAPY | PHARMACOLOGY & PHARMACY | ATM | CYTOTOXICITY | DNA-Activated Protein Kinase - antagonists & inhibitors | Cell Survival - drug effects | HCT116 Cells | Humans | Morpholines - pharmacology | Cisplatin - pharmacology | Comet Assay | Organoplatinum Compounds - pharmacology | Drug Synergism | HT29 Cells | Topoisomerase I Inhibitors - pharmacology | Cell Cycle Checkpoints - drug effects | Colonic Neoplasms - pathology | Acridones - pharmacology | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Chromones - pharmacology | Camptothecin - pharmacology | Camptothecin - analogs & derivatives | Antimitotic agents | Complications and side effects | Colon cancer | DNA damage | Dosage and administration | Research | Antineoplastic agents | Drug therapy | Studies | Pharmacology | Deoxyribonucleic acid--DNA | Colorectal cancer | Drugs | Flow cytometry | Phosphorylation | Data processing | Tumor cell lines | Synergism | Comet assay | Western blotting | Homologous recombination repair | Irinotecan | Rad51 protein | DNA-dependent protein kinase | homologous recombination | Cell cycle | oxaliplatin
Journal Article